KRINTAFEL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Krintafel, and when can generic versions of Krintafel launch?
Krintafel is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in KRINTAFEL is tafenoquine succinate. Two suppliers are listed for this compound. Additional details are available on the tafenoquine succinate profile page.
Summary for KRINTAFEL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 44 |
| Clinical Trials: | 1 |
| Patent Applications: | 27 |
| Drug Prices: | Drug price information for KRINTAFEL |
| What excipients (inactive ingredients) are in KRINTAFEL? | KRINTAFEL excipients list |
| DailyMed Link: | KRINTAFEL at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for KRINTAFEL
Generic Entry Date for KRINTAFEL*:
Constraining patent/regulatory exclusivity:
INDICATED FOR THE RADICAL CURE (PREVENTION OF RELAPSE) OF PLASMODIUM VIVAX MALARIA IN PATIENTS AGED 16 YEARS AND OLDER WHO ARE RECEIVING APPROPRIATE ANTIMALARIAL THERAPY FOR ACUTE P. VIVAX INFECTION NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for KRINTAFEL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Shoklo Malaria Research Unit | Phase 4 |
| Mahidol Oxford Tropical Medicine Research Unit | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for KRINTAFEL
US Patents and Regulatory Information for KRINTAFEL
KRINTAFEL is protected by zero US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of KRINTAFEL is ⤷ Try a Trial.
This potential generic entry date is based on INDICATED FOR THE RADICAL CURE (PREVENTION OF RELAPSE) OF PLASMODIUM VIVAX MALARIA IN PATIENTS AGED 16 YEARS AND OLDER WHO ARE RECEIVING APPROPRIATE ANTIMALARIAL THERAPY FOR ACUTE P. VIVAX INFECTION.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting KRINTAFEL
INDICATED FOR THE RADICAL CURE (PREVENTION OF RELAPSE) OF PLASMODIUM VIVAX MALARIA IN PATIENTS AGED 16 YEARS AND OLDER WHO ARE RECEIVING APPROPRIATE ANTIMALARIAL THERAPY FOR ACUTE P. VIVAX INFECTION
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | KRINTAFEL | tafenoquine succinate | TABLET;ORAL | 210795-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
